57 institutions hold shares in TFF Pharmaceuticals Inc. (TFFP), with 3.77M shares held by insiders accounting for 16.31% while institutional investors hold 33.65% of the company’s shares. The shares outstanding are 20.43M, and float is at 17.74M with Short Float at 2.47%. Institutions hold 28.16% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Nantahala Capital Management, LLC with over 1.76 million shares valued at $25.25 million. The investor’s holdings represent 7.62% of the TFFP Shares outstanding. As of Dec 30, 2020, the second largest holder is Corriente Advisors, LLC with 1.35 million shares valued at $19.33 million to account for 5.83% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 0.63 million shares representing 2.71% and valued at over $8.98 million, while Hudson Bay Capital Management LP holds 2.16% of the shares totaling 0.5 million with a market value of $7.16 million.
TFF Pharmaceuticals Inc. (NASDAQ: TFFP) is -21.51% lower on its value in year-to-date trading and has touched a low of $4.20 and a high of $21.14 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TFFP stock was last observed hovering at around $11.15 in the last trading session, with the day’s gains setting it 0.09% off its average median price target of $31.50 for the next 12 months. It is also 69.62% off the consensus price target high of $37.00 offered by 4 analysts, but current levels are 53.17% higher than the price target low of $24.00 for the same period.
Currently trading at $11.24, the stock is -14.83% and -24.90% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.53 million and changing 0.81% at the moment leaves the stock -21.19% off its SMA200. TFFP registered 160.19% gain for a year compared to 6-month gain of -25.17%. The firm has a 50-day simple moving average (SMA 50) of $15.29 and a 200-day simple moving average (SMA200) of $15.89.
The stock witnessed a -34.54% loss in the last 1 month and extending the period to 3 months gives it a -43.09%, and is -9.94% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.58% over the week and 6.38% over the month.
Distance from 52-week low is 167.62% and -46.83% from its 52-week high.
TFF Pharmaceuticals Inc. (TFFP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for TFF Pharmaceuticals Inc. (TFFP) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
TFF Pharmaceuticals Inc. is expected to release its quarterly report on 08/19/2021 and quarterly earnings per share for the current quarter are estimated at -$0.24.The EPS is expected to grow by 54.30% this year.
TFF Pharmaceuticals Inc. (TFFP) Insider Activity
A total of 45 insider transactions have happened at TFF Pharmaceuticals Inc. (TFFP) in the last six months, with sales accounting for 24 and purchases happening 21 times. The most recent transaction is an insider sale by Lung Therapeutics, Inc., the company’s 10% Owner. SEC filings show that Lung Therapeutics, Inc. sold 715,000 shares of the company’s common stock on Mar 26 at a price of $14.00 per share for a total of $10.01 million. Following the sale, the insider now owns 2.23 million shares.
TFF Pharmaceuticals Inc. disclosed in a document filed with the SEC on Mar 15 that ROCAMBOLI STEPHEN (Director) sold a total of 20,006 shares of the company’s common stock. The trade occurred on Mar 15 and was made at $16.85 per share for $0.34 million. Following the transaction, the insider now directly holds 15722.0 shares of the TFFP stock.
Still, SEC filings show that on Mar 15, Mattes Glenn R. (President and CEO) disposed off 50,000 shares at an average price of $17.04 for $0.85 million. The insider now directly holds 10,000 shares of TFF Pharmaceuticals Inc. (TFFP).